Favorable outcomes seen for very late-onset myasthenia gravis: Study
Most people with very late-onset myasthenia gravis (MG) — patients in whom symptoms start to manifest at age…
Articles by Katherine Poinsatte, PhD
FDA grants nipocalimab priority review for the treatment of gMG
The U.S. Food and Drug Administration (FDA) has granted priority review to Johnson & Johnson’s request to…
Soleo Health opens ambulatory infusion center in Denver area
Soleo Health, a specialty pharmacy company, has opened a new ambulatory infusion site in the…
IVIG treatment for MG linked with high medical costs in Norway: Study
Myasthenia gravis (MG) patients in Norway who were treated with intravenous immunoglobulin (IVIG) had 2.3 times higher direct…
Statin treatment may increase risk of MG onset, worsening: Study
Patients should be monitored for symptoms of myasthenia gravis (MG) for approximately six months after starting treatment with…
Rare thymus mass found in man, 70, with myasthenia gravis
A 70-year-old man was diagnosed with myasthenia gravis (MG) and with a mass in his thymus, a small, immune…
Long-term use of tacrolimus found safe, effective in MG in study
Long-term use of the immunosuppressant tacrolimus was found to be safe and effective in myasthenia gravis (MG) patients with…
First generalized MG patient dosed in immune-modifying therapy trial
The first patient has been dosed in a proof-of-concept clinical trial evaluating CNP-106, an immune-modifying nanoparticle that’s designed to reprogram…
Analysis of online posts reveals impact of disease symptoms
An artificial intelligence (AI)-powered analysis of more than 11,000 posts on social media or in online community groups found that…
Early treatment with Prograf found safe, effective for juvenile MG
Treatment with the immunosuppressant Prograf (tacrolimus) within one year of the onset of juvenile myasthenia gravis (JMG) was…